1. Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Issue 12 (9th October 2018) Authors: Leiter, L. A.; Tinahones, F. J.; Karalis, D. G.; Bujas‐Bobanovic, M.; Letierce, A.; Mandel, J.; Samuel, R.; Jones, P. H. Journal: Diabetic medicine Issue: Volume 35:Issue 12(2018) Page Start: 1742 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials. Issue 1 (31st August 2017) Authors: Leiter, L. A.; Müller‐Wieland, D.; Baccara‐Dinet, M. T.; Letierce, A.; Samuel, R.; Cariou, B. Journal: Diabetic medicine Issue: Volume 35:Issue 1(2018) Page Start: 121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Regional Variations In Alirocumab Dosing Patterns During An Open-Label Extension Study In Patients With Heterozygous Familial Hypercholesterolaemia. (August 2019) Authors: Langslet, G.; Hovingh, G.K.; Guyton, J.R.; Baccara-Dinet, M.T.; Letierce, A.; Manvelian, G.; Farnier, M. Journal: Atherosclerosis Issue: Volume 287(2019) Page Start: e37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. THU0294 Regulatory T cells/TH17 balance in the pathogenesis of pediatric behçet disease. (23rd January 2014) Authors: Tran, T.-A.; Hubert, A.; Letierce, A.; Terrier, B.; Geri, G.; Saadoun, D.; Kone-Paut, I.; Rosenzwajg, M. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 255 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗